Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer

We identified critical prognostic associations between GSRlncRNAs and BLCA. Based on these findings, we constructed a GSRlncRNA-based predictive signature, which demonstrated considerable potential for risk stratification and personalized treatment decisions. Functional experiments further validated the involvement of GSRlncRNAs in BLCA progression.